Classification and pathogenesis of meningococcal infections

Methods in Molecular Biology

Volumn 799, Issue , 2012, Pages 21-35

  Brandtzaeg, Petter ^a   van Deuren, Marcel ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Classification; Lipopolysaccharide; Meningococcal meningitis; Septicemia; Shock

Indexed keywords

BACTERIAL DNA; LIPOPOLYSACCHARIDE;

ANIMAL; ANIMAL MODEL; ARTICLE; BLOOD; CHEMISTRY; CLASSIFICATION; COMPLEMENT ACTIVATION; EPIDEMIC MENINGITIS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MENINGOCOCCOSIS; MICROBIOLOGY; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; RESEARCH; SEPTIC SHOCK; SWINE;

ANIMALS; COMPLEMENT ACTIVATION; DNA, BACTERIAL; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; MODELS, ANIMAL; NEISSERIA MENINGITIDIS; RESEARCH; SHOCK, SEPTIC; SWINE; WATERHOUSE-FRIDERICHSEN SYNDROME;

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS;

EID: 80555156127     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-346-2_2     Document Type: Chapter

References (59)

1. Caugant DA, Maiden MC (2009) Meningococcal carriage and disease-population biology and evolution. Vaccine 27 Suppl 2:B64–B70
2. Virji M (2009) Pathogenic neisseriae: surface modulation, pathogenesis and infection control. Nat Rev Microbiol 7:274–286
3. Stephens DS, Farley MM (1991) Pathogenic events during infection of the human nasophar-ynx with Neisseria meningitidis and Haemophilus influenzae. Rev Infect Dis 13:22–33
4. Flexner S (1913) The results of serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 17:553–576
5. Brooks R, Woods CW, Benjamin DK Jr et al (2006) Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 43:49–54
6. de Greeff SC, de Melker HE, Schouls LM et al (2008) Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005. Eur J Clin Microbiol Infect Dis 27:985–992
7. Rosenstein NE, Perkins BA, Stephens DS et al (1999) The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 180:1894–1901
8. Gedde-Dahl TW, Hoiby EA, Schillinger A et al (1983) An epidemiological, clinical and microbiological follow-up study of incident meningococcal disease cases in Norway, winter 1981-1982. Material and epidemiology in the MenOPP project. NIPH Ann 6:155–168
9. Halstensen A, Pedersen SH, Haneberg B et al (1987) Case fatality of meningococcal disease in western Norway. Scand J Infect Dis 19:35–42
10. Brandtzaeg P, Kierulf P, Gaustad P et al (1989) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195–204
11. van Deuren M, Brandtzaeg P, van der Meer JW (2000) Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 13:144–66
12. Boisier P, Mainassara HB, Sidikou F et al (2007) Case-fatality ratio of bacterial meningitis in the African meningitis belt: we can do better. Vaccine 25 Suppl 1:A24–A29
13. Rosenstein NE, Perkins BA, Stephens DS et al (2001) Meningococcal disease. N Engl J Med 344:1378–1388
14. Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcae-mia, and Neisseria meningitidis. Lancet 369:2196–2210
15. Davila S, Wright VJ, Khor CC et al (2010) Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 42:772–776
16. Haralambous E, Dolly SO, Hibberd ML et al (2006) Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 38:764–771
17. Brouwer MC, Read RC, van de Beek D (2010) Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 10:262–274
18. Stiehm ER, Damrosch DS (1966) Factors in the prognosis of meningococcal infection. Review of 63 cases with emphasis on recognition and management of the severely ill patient. J Pediatr 68:457–467
19. Brandtzaeg P (2006) Pathogenesis and pathophysiology of invasive meningococcal disease. In: Frosch M, Maiden CJ (eds) Handbook of meningococcal disease. Wiley-VCH, Weinheim, pp 427–480
20. Brandtzaeg P (2010) Meningococcal Infections. In: Warrell DA, Cox TM, Firth JD (eds) Oxford Textbook of Medicine, 5th edn. Oxford University Press, Oxford, pp 709–722
21. Hackett SJ, Guiver M, Marsh J et al (2002) Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Child 86:44–46
22. Darton T, Guiver M, Naylor S et al (2009) Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis 48:587–594
23. Ovstebo R, Brandtzaeg P, Brusletto B et al (2004) Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 42:2980–2987
24. Harrison OB, Robertson BD, Faust SN et al (2002) Analysis of pathogen-host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo. Infect Immun 70:5193–5201
25. van Deuren M, van Dijke BJ, Koopman RJ et al (1993) Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions. BMJ 306:1229–1232
26. van Deuren M, Brandtzaeg P (2005) Myocardial dysfunction in meningococcal septic shock: no clear answer yet. Crit Care Med 33:1884–1886
27. Baines PB, Stanford S, Bishop-Bailey D et al (1999) Nitric oxide production in meningococcal disease is directly related to disease severity. Crit Care Med 27:1187–1190
28. Bjerre A, Brusletto B, Rosenqvist E et al (2000) Cellular activating properties and morphology of membrane-bound and purified meningococcal lipopolysaccharide. J Endotoxin Res 6:437–445
29. Brandtzaeg P, Bjerre A, Ovstebo R et al (2001) Neisseria meningitidis lipopolysaccharides in human pathology. J Endotoxin Res 7:401–420
30. Bjerre A, Brusletto B, Ovstebo R et al (2003) Identification of meningococcal LPS as a major monocyte activator in IL-10 depleted shock plasmas and CSF by blocking the CD14-TLR4 receptor complex. J Endotoxin Res 9:155–163
31. Hellerud BC, Stenvik J, Espevik T et al (2008) Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation. Infect Immun 76:4183–4189
32. Sprong T, Stikkelbroeck N, van der Ley P et al (2001) Contributions of Neisseria meningitidis LPS and non-LPS to proinflammatory cytokine response. J Leukoc Biol 70:283–288
33. Girardin SE, Travassos LH, Herve M et al (2003) Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 278:41702–41708
34. Ingalls RR, Lien E, Golenbock DT (2001) Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through toll-like receptor 2. Infect Immun 69:2230–2236
35. Massari P, Ram S, Macleod H et al (2003) The role of porins in neisserial pathogenesis and immunity. Trends Microbiol 11:87–93
36. Mogensen TH, Paludan SR, Kilian M et al (2006) Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol 80:267–277
37. Pridmore AC, Wyllie DH, Abdillahi F et al (2001) A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 183:89–96
38. Kahler CM, Stephens DS (1998) Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endo-toxin). Crit Rev Microbiol 24:281–334
39. Kulshin VA, Zahringer U, Lindner B et al (1992) Structural characterization of the lipid A component of pathogenic Neisseria meningitidis. J Bacteriol 174:1793–1800
40. Zughaier S, Agrawal S, Stephens DS et al (2006) Hexa-acylation and KDO(2)-glycosylation determine the specific immunostimulatory activity of Neisseria meningitidis lipid A for human monocyte derived dendritic cells. Vaccine 24:1291–1297
41. Scholten RJ, Kuipers B, Valkenburg HA et al (1994) Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med Microbiol 41:236–243
42. van der Ley P, Steeghs L, Hamstra HJ et al (2001) Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 69:5981–5990
43. Fransen F, Heckenberg SG, Hamstra HJ et al (2009) Naturally occurring lipid A mutants in Neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy. PLoS Pathog 5:e1000396
44. John CM, Liu M, Jarvis GA (2009) Natural phosphoryl and acyl variants of lipid A from Neisseria meningitidis strain 89I differentially induce tumor necrosis factor-alpha in human monocytes. J Biol Chem 284:21515–21525
45. Zhang Y, Gaekwad J, Wolfert MA et al (2008) Innate immune responses of synthetic lipid A derivatives of Neisseria meningitidis. Chemistry 14:558–569
46. Zimmer SM, Zughaier SM, Tzeng YL et al (2007) Human MD-2 discrimination of meningococcal lipid A structures and activation of TLR4. Glycobiology 17:847–856
47. Steeghs L, den Hartog R, den Boer A et al (1998) Meningitis bacterium is viable without endotoxin. Nature 392:449–450
48. Albiger B, Johansson L, Jonsson AB (2003) Lipooligosaccharide-deficient Neisseria meningitidis shows altered pilus-associated characteristics. Infect Immun 71:155–162
49. Brandtzaeg P (2003) Host response to Neisseria meningitidis lacking lipopolysaccharides. Expert Rev Anti Infect Ther 1:589–596
50. Brandtzaeg P, Mollnes TE, Kierulf P (1989) Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 160:58–65
51. Bjerre A, Brusletto B, Mollnes TE et al (2002) Complement activation induced by purified Neisseria meningitidis lipopolysaccharide (LPS), outer membrane vesicles, whole bacteria, and an LPS-free mutant. J Infect Dis 185:220–228
52. Ovstebo R, Olstad OK, Brusletto B et al (2008) Identification of genes particularly sensitive to lipopolysaccharide (LPS) in human monocytes induced by wild-type versus LPS-deficient Neisseria meningitidis strains. Infect Immun 76:2685–2695
53. Schubert-Unkmeir A, Sokolova O, Panzner U et al (2007) Gene expression pattern in human brain endothelial cells in response to Neisseria meningitidis. Infect Immun 75:899–914
54. Christodoulides M, Heckels JE, Weller RO (2002). The role of the leptomeninges in meningococcal meningitis. In: Ferreiros C, Criado MT, and Vavquez J (eds) Emerging strategies in the fight against meningitis: molecular and cellular aspects. Horizon Scientific Press, Norfolk: pp1–34
55. Join-Lambert O, Morand PC, Carbonnelle E et al (2010) Mechanisms of meningeal invasion by a bacterial extracellular pathogen, the example of Neisseria meningitidis. Prog Neurobiol 91:130–139
56. Wells DB, Tighe PJ, Wooldridge KG et al (2001) Differential gene expression during meningeal-meningococcal interaction: evidence for self-defense and early release of cytokines and chemokines. Infect Immun 69:2718–2722
57. Zughaier SM, Zimmer SM, Datta A et al (2005) Differential induction of the toll-like receptor 4-MyD88-dependent and-independent signaling pathways by endotoxins. Infect Immun 73: 2940–2950
58. Nielsen EW, Hellerud BC, Thorgersen EB et al (2009) A new dynamic porcine model of meningococcal shock. Shock 32:302–309
59. Hellerud BC, Nielsen EW, Thorgersen EB et al (2010) Dissecting the effects of lipopolysaccharides from nonlipopolysaccharide molecules in experimental porcine meningococcal sepsis. Crit Care Med 38:1467–1474